Nearly all multicellular organisms undergo progressive degradation of physiological function as they get older-that is, they age. Over the last two decades remarkable insights into the molecular regulation of conserved genetic pathways underlying stress resistance and other age-related phenotypes raises the prospect that specific pharmacological interventions can be identified that will enhance human health throughout the entirety of their lifespan. A major concern here, however, is that the response of any particular individual to a drug treatment may be highly dependent on their specific genetic background; something that has been observed in a number of studies. The hope, therefore, is to identify drug interventions that maintain their desired effects even in the face of substantial genetic variation within a population. The nematode genus Caenorhabditis provides an ideal context for addressing this issue because (1) much of the fundamental biology of the critical target pathways has been conducted using a member of this group (C. elegans) and (2) very similar experimental approaches can be used to test drug-intervention responses of a set of related species that span a broad range of potential genetic backgrounds, equivalent to the distance between mice and humans. The goal of the Caenorhabditis Intervention Testing Program (CITP) is to examine a variety of pharmacological agents for consistent effects across these species (and natural isolates within species). Here, we aim to (1) measure the effect of pharmacological interventions on the lifespan of multiple nematode species, (2) evaluate the impact of pharmacological interventions on physiological and biochemical measures of health, and (3) analyze the specific molecular and physiological functions hypothesized to underlie intervention-induced increases in lifespan and health measures. These experiments will be carried out using a variety of innovative assays that allow high throughput, high precision estimates of individual longevity, physiology, behavior and health. Project goals will be achieved via a joint management structure that is overseen by a Steering Committee of program participants and selected outside members, with drug candidates selected by an appointed Access Panel. All experimental outcomes will be made available to the broader scientific community, as well as being published in the scientific literature. Identifying drug treatments tha enhance health and physiological performance, particularly in regard to holding back the regular degradation of function usually associated with aging, has the potential to revolutionize the manner which people age-prolonging healthy states much later into life-thereby decreasing costs of healthcare delivery in an increasingly aging society.

Public Health Relevance

We have learned a great deal about the biology underlying the normal progression toward aging, including identifying specific response systems that can help to delay the onset of the loss of biological function usually associated with growing older. Our next steps are to identify drugs that may be able to activate these systems in the absence of their usual cues (e.g., starvation and stress), thereby preserving human health and normal activity well into old age.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Kohanski, Ronald A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oregon
Organized Research Units
United States
Zip Code
Lucanic, Mark; Plummer, W Todd; Chen, Esteban et al. (2017) Impact of genetic background and experimental reproducibility on identifying chemical compounds with robust longevity effects. Nat Commun 8:14256
Lithgow, Gordon J; Driscoll, Monica; Phillips, Patrick (2017) A long journey to reproducible results. Nature 548:387-388